PMID- 31427916
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231013
IS  - 1662-4548 (Print)
IS  - 1662-453X (Electronic)
IS  - 1662-453X (Linking)
VI  - 13
DP  - 2019
TI  - Therapeutic Potential of Neurotrophins for Repair After Brain Injury: A Helping 
      Hand From Biomaterials.
PG  - 790
LID - 10.3389/fnins.2019.00790 [doi]
LID - 790
AB  - Stroke remains the leading cause of long-term disability with limited options 
      available to aid in recovery. Significant effort has been made to try and 
      minimize neuronal damage following stroke with use of neuroprotective agents, 
      however, these treatments have yet to show clinical efficacy. Regenerative 
      interventions have since become of huge interest as they provide the potential to 
      restore damaged neural tissue without being limited by a narrow therapeutic 
      window. Neurotrophins, such as brain-derived neurotrophic factor (BDNF), and 
      their high affinity receptors are actively produced throughout the brain and are 
      involved in regulating neuronal activity and normal day-to-day function. 
      Furthermore, neurotrophins are known to play a significant role in both 
      protection and recovery of function following neurodegenerative diseases such as 
      stroke and traumatic brain injury (TBI). Unfortunately, exogenous administration 
      of these neurotrophins is limited by a lack of blood-brain-barrier (BBB) 
      permeability, poor half-life, and rapid degradation. Therefore, we have focused 
      this review on approaches that provide a direct and sustained neurotrophic 
      support using pharmacological therapies and mimetics, physical activity, and 
      potential drug delivery systems, including discussion around advantages and 
      limitations for use of each of these systems. Finally, we discuss future 
      directions of biomaterial drug-delivery systems, including the incorporation of 
      heparan sulfate (HS) in conjunction with neurotrophin-based interventions.
FAU - Houlton, Josh
AU  - Houlton J
AD  - Brain Health Research Centre, Department of Anatomy, University of Otago, 
      Dunedin, New Zealand.
FAU - Abumaria, Nashat
AU  - Abumaria N
AD  - State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain 
      Science, Institute of Brain Science, Fudan University, Shanghai, China.
AD  - Department of Laboratory Animal Science, Shanghai Medical College, Fudan 
      University, Shanghai, China.
FAU - Hinkley, Simon F R
AU  - Hinkley SFR
AD  - The Ferrier Research Institute, Victoria University of Wellington, Petone, New 
      Zealand.
FAU - Clarkson, Andrew N
AU  - Clarkson AN
AD  - Brain Health Research Centre, Department of Anatomy, University of Otago, 
      Dunedin, New Zealand.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190802
PL  - Switzerland
TA  - Front Neurosci
JT  - Frontiers in neuroscience
JID - 101478481
PMC - PMC6688532
OTO - NOTNLM
OT  - BDNF
OT  - HSPG
OT  - Trk receptor
OT  - electrospun fibers
OT  - hydrogel
OT  - microsphere encapsulation
OT  - neurotrophins
OT  - p75 neurotrophic receptor
EDAT- 2019/08/21 06:00
MHDA- 2019/08/21 06:01
PMCR- 2019/01/01
CRDT- 2019/08/21 06:00
PHST- 2019/03/14 00:00 [received]
PHST- 2019/07/15 00:00 [accepted]
PHST- 2019/08/21 06:00 [entrez]
PHST- 2019/08/21 06:00 [pubmed]
PHST- 2019/08/21 06:01 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 10.3389/fnins.2019.00790 [doi]
PST - epublish
SO  - Front Neurosci. 2019 Aug 2;13:790. doi: 10.3389/fnins.2019.00790. eCollection 
      2019.